[{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"SyneuRx","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Sodium Benzoate","moa":"Amino acid metabolism","graph1":"Psychiatry\/Psychology","graph2":"Phase II\/ Phase III","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"9","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2014","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Immunology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2019","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"CytoDyn","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2016","type":"Inapplicable","leadProduct":"Leronlimab","moa":"C-C chemokine receptor type 5","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"10","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Peptide, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Interleukin-7","moa":"IL-7R","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"AMTX-100","moa":"NFkB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Powder","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Sirnaomics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2020","type":"Inapplicable","leadProduct":"STP705","moa":"TGF-beta-1\/COX-2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Oncology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Oligonucleotide","year":"2023","type":"Inapplicable","leadProduct":"Rintatolimod","moa":"Toll-like receptor 3","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Amnio Matrix","moa":"Undisclosed","graph1":"Podiatry","graph2":"Undisclosed","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"1","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"AMTX-100 CF","moa":"Undisclosed","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amarantus BioScience Holdings","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"Autologous Engineered Skin Substitute","moa":"Undisclosed","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Sheet","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"MT101-5","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amarex Clinical Research","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"CHINA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Progerinin","moa":"Undisclosed","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"X-121","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"6","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"}]
Find Clinical Drug Pipeline Developments & Deals by Amarex Clinical Research
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
